Cargando…

Topical Application of Deglycating Enzymes as an Alternative Non-Invasive Treatment for Presbyopia

Presbyopia is an age-related vision disorder that is a global public health problem. Up to 85% of people aged ≥40 years develop presbyopia. In 2015, 1.8 billion people globally had presbyopia. Of those with significant near vision disabilities due to uncorrected presbyopia, 94% live in developing co...

Descripción completa

Detalles Bibliográficos
Autores principales: Delanghe, Joris R., Beeckman, Jeroen, Beerens, Koen, Himpe, Jonas, Bostan, Nezahat, Speeckaert, Marijn M., Notebaert, Margo, Huizing, Manon, Van Aken, Elisabeth
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10139041/
https://www.ncbi.nlm.nih.gov/pubmed/37108506
http://dx.doi.org/10.3390/ijms24087343
_version_ 1785032850465095680
author Delanghe, Joris R.
Beeckman, Jeroen
Beerens, Koen
Himpe, Jonas
Bostan, Nezahat
Speeckaert, Marijn M.
Notebaert, Margo
Huizing, Manon
Van Aken, Elisabeth
author_facet Delanghe, Joris R.
Beeckman, Jeroen
Beerens, Koen
Himpe, Jonas
Bostan, Nezahat
Speeckaert, Marijn M.
Notebaert, Margo
Huizing, Manon
Van Aken, Elisabeth
author_sort Delanghe, Joris R.
collection PubMed
description Presbyopia is an age-related vision disorder that is a global public health problem. Up to 85% of people aged ≥40 years develop presbyopia. In 2015, 1.8 billion people globally had presbyopia. Of those with significant near vision disabilities due to uncorrected presbyopia, 94% live in developing countries. Presbyopia is undercorrected in many countries, with reading glasses available for only 6–45% of patients living in developing countries. The high prevalence of uncorrected presbyopia in these parts of the world is due to the lack of adequate diagnosis and affordable treatment. The formation of advanced glycation end products (AGEs) is a non-enzymatic process known as the Maillard reaction. The accumulation of AGEs in the lens contributes to lens aging (leading to presbyopia and cataract formation). Non-enzymatic lens protein glycation induces the gradual accumulation of AGEs in aging lenses. AGE-reducing compounds may be effective at preventing and treating AGE-related processes. Fructosyl-amino acid oxidase (FAOD) is active on both fructosyl lysine and fructosyl valine. As the crosslinks encountered in presbyopia are mainly non-disulfide bridges, and based on the positive results of deglycating enzymes in cataracts (another disease caused by glycation of lens proteins), we studied the ex vivo effects of topical FAOD treatment on the power of human lenses as a new potential non-invasive treatment for presbyopia. This study demonstrated that topical FAOD treatment resulted in an increase in lens power, which is approximately equivalent to the correction obtained by most reading glasses. The best results were obtained for the newer lenses. Simultaneously, a decrease in lens opacity was observed, which improved lens quality. We also demonstrated that topical FAOD treatment results in a breakdown of AGEs, as evidenced by gel permeation chromatography and a marked reduction in autofluorescence. This study demonstrated the therapeutic potential of topical FAOD treatment in presbyopia.
format Online
Article
Text
id pubmed-10139041
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-101390412023-04-28 Topical Application of Deglycating Enzymes as an Alternative Non-Invasive Treatment for Presbyopia Delanghe, Joris R. Beeckman, Jeroen Beerens, Koen Himpe, Jonas Bostan, Nezahat Speeckaert, Marijn M. Notebaert, Margo Huizing, Manon Van Aken, Elisabeth Int J Mol Sci Article Presbyopia is an age-related vision disorder that is a global public health problem. Up to 85% of people aged ≥40 years develop presbyopia. In 2015, 1.8 billion people globally had presbyopia. Of those with significant near vision disabilities due to uncorrected presbyopia, 94% live in developing countries. Presbyopia is undercorrected in many countries, with reading glasses available for only 6–45% of patients living in developing countries. The high prevalence of uncorrected presbyopia in these parts of the world is due to the lack of adequate diagnosis and affordable treatment. The formation of advanced glycation end products (AGEs) is a non-enzymatic process known as the Maillard reaction. The accumulation of AGEs in the lens contributes to lens aging (leading to presbyopia and cataract formation). Non-enzymatic lens protein glycation induces the gradual accumulation of AGEs in aging lenses. AGE-reducing compounds may be effective at preventing and treating AGE-related processes. Fructosyl-amino acid oxidase (FAOD) is active on both fructosyl lysine and fructosyl valine. As the crosslinks encountered in presbyopia are mainly non-disulfide bridges, and based on the positive results of deglycating enzymes in cataracts (another disease caused by glycation of lens proteins), we studied the ex vivo effects of topical FAOD treatment on the power of human lenses as a new potential non-invasive treatment for presbyopia. This study demonstrated that topical FAOD treatment resulted in an increase in lens power, which is approximately equivalent to the correction obtained by most reading glasses. The best results were obtained for the newer lenses. Simultaneously, a decrease in lens opacity was observed, which improved lens quality. We also demonstrated that topical FAOD treatment results in a breakdown of AGEs, as evidenced by gel permeation chromatography and a marked reduction in autofluorescence. This study demonstrated the therapeutic potential of topical FAOD treatment in presbyopia. MDPI 2023-04-16 /pmc/articles/PMC10139041/ /pubmed/37108506 http://dx.doi.org/10.3390/ijms24087343 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Delanghe, Joris R.
Beeckman, Jeroen
Beerens, Koen
Himpe, Jonas
Bostan, Nezahat
Speeckaert, Marijn M.
Notebaert, Margo
Huizing, Manon
Van Aken, Elisabeth
Topical Application of Deglycating Enzymes as an Alternative Non-Invasive Treatment for Presbyopia
title Topical Application of Deglycating Enzymes as an Alternative Non-Invasive Treatment for Presbyopia
title_full Topical Application of Deglycating Enzymes as an Alternative Non-Invasive Treatment for Presbyopia
title_fullStr Topical Application of Deglycating Enzymes as an Alternative Non-Invasive Treatment for Presbyopia
title_full_unstemmed Topical Application of Deglycating Enzymes as an Alternative Non-Invasive Treatment for Presbyopia
title_short Topical Application of Deglycating Enzymes as an Alternative Non-Invasive Treatment for Presbyopia
title_sort topical application of deglycating enzymes as an alternative non-invasive treatment for presbyopia
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10139041/
https://www.ncbi.nlm.nih.gov/pubmed/37108506
http://dx.doi.org/10.3390/ijms24087343
work_keys_str_mv AT delanghejorisr topicalapplicationofdeglycatingenzymesasanalternativenoninvasivetreatmentforpresbyopia
AT beeckmanjeroen topicalapplicationofdeglycatingenzymesasanalternativenoninvasivetreatmentforpresbyopia
AT beerenskoen topicalapplicationofdeglycatingenzymesasanalternativenoninvasivetreatmentforpresbyopia
AT himpejonas topicalapplicationofdeglycatingenzymesasanalternativenoninvasivetreatmentforpresbyopia
AT bostannezahat topicalapplicationofdeglycatingenzymesasanalternativenoninvasivetreatmentforpresbyopia
AT speeckaertmarijnm topicalapplicationofdeglycatingenzymesasanalternativenoninvasivetreatmentforpresbyopia
AT notebaertmargo topicalapplicationofdeglycatingenzymesasanalternativenoninvasivetreatmentforpresbyopia
AT huizingmanon topicalapplicationofdeglycatingenzymesasanalternativenoninvasivetreatmentforpresbyopia
AT vanakenelisabeth topicalapplicationofdeglycatingenzymesasanalternativenoninvasivetreatmentforpresbyopia